$TRVI
Trevi Therapeutics, Inc.

2024 Q4 Form 10-Q Financial Statement

#000095017024122355 Filed on November 06, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.863M
YoY Change 5.26%
% of Gross Profit
Research & Development $11.22M
YoY Change 77.51%
% of Gross Profit
Depreciation & Amortization $36.00K
YoY Change -10.0%
% of Gross Profit
Operating Expenses $14.09M
YoY Change 55.74%
Operating Profit -$14.09M
YoY Change 55.74%
Interest Expense $825.0K
YoY Change 27400.0%
% of Operating Profit
Other Income/Expense, Net $814.0K
YoY Change -38.98%
Pretax Income -$13.27M
YoY Change 72.13%
Income Tax -$31.00K
% Of Pretax Income
Net Earnings -$13.24M
YoY Change 72.02%
Net Earnings / Revenue
Basic Earnings Per Share -$0.13
Diluted Earnings Per Share -$0.13
COMMON SHARES
Basic Shares Outstanding 76.87M 72.59M
Diluted Shares Outstanding 101.3M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $65.49M
YoY Change -26.33%
Cash & Equivalents $16.05M
Short-Term Investments $49.44M
Other Short-Term Assets $667.0K
YoY Change -36.23%
Inventory
Prepaid Expenses $1.176M
Receivables
Other Receivables
Total Short-Term Assets $67.34M
YoY Change -28.33%
LONG-TERM ASSETS
Property, Plant & Equipment $174.0K
YoY Change -26.89%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $256.0K
YoY Change -13.8%
Total Long-Term Assets $1.572M
YoY Change -19.09%
TOTAL ASSETS
Total Short-Term Assets $67.34M
Total Long-Term Assets $1.572M
Total Assets $68.91M
YoY Change -28.14%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.614M
YoY Change 28.5%
Accrued Expenses $7.212M
YoY Change 98.95%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $62.00K
YoY Change -38.0%
Total Short-Term Liabilities $9.123M
YoY Change 76.36%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change -100.0%
Other Long-Term Liabilities $816.0K
YoY Change -25.82%
Total Long-Term Liabilities $816.0K
YoY Change -32.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.123M
Total Long-Term Liabilities $816.0K
Total Liabilities $9.939M
YoY Change 58.11%
SHAREHOLDERS EQUITY
Retained Earnings -$275.6M
YoY Change 19.16%
Common Stock $75.00K
YoY Change 17.19%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $58.97M
YoY Change
Total Liabilities & Shareholders Equity $68.91M
YoY Change -28.14%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$13.24M
YoY Change 72.02%
Depreciation, Depletion And Amortization $36.00K
YoY Change -10.0%
Cash From Operating Activities -$9.556M
YoY Change 31.26%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $7.667M
YoY Change -57.41%
Cash From Investing Activities $7.667M
YoY Change -57.36%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.978M
YoY Change 229.67%
NET CHANGE
Cash From Operating Activities -9.556M
Cash From Investing Activities 7.667M
Cash From Financing Activities 4.978M
Net Change In Cash 3.089M
YoY Change -74.7%
FREE CASH FLOW
Cash From Operating Activities -$9.556M
Capital Expenditures $0.00
Free Cash Flow -$9.556M
YoY Change 30.9%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001563880
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38886
dei Entity Registrant Name
EntityRegistrantName
TREVI THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
45-0834299
dei Entity Address Address Line1
EntityAddressAddressLine1
195 Church Street
dei Entity Address Address Line2
EntityAddressAddressLine2
16th Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
New Haven
dei Entity Address State Or Province
EntityAddressStateOrProvince
CT
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
06510
dei City Area Code
CityAreaCode
203
dei Local Phone Number
LocalPhoneNumber
304-2499
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
dei Trading Symbol
TradingSymbol
TRVI
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
76865711
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16052000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
32397000
CY2024Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
49441000
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
50574000
CY2024Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1176000
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
3621000
CY2024Q3 us-gaap Other Assets Current
OtherAssetsCurrent
667000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
955000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
67336000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
87547000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
973000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1137000
CY2024Q3 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
169000
CY2023Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
206000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
174000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
216000
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
256000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
297000
CY2024Q3 us-gaap Assets
Assets
68908000
CY2023Q4 us-gaap Assets
Assets
89403000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1614000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1809000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7212000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3709000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
235000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
184000
CY2024Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
62000
CY2023Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
122000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
9123000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5824000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
816000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1001000
CY2023Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
31000
CY2024Q3 us-gaap Liabilities
Liabilities
9939000
CY2023Q4 us-gaap Liabilities
Liabilities
6856000
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
75454375
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
75454375
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
68283699
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
68283699
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
75000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
68000
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
334385000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
321642000
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
139000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-29000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-275630000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-239134000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
58969000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
82547000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
68908000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
89403000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11224000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6323000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
30049000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17165000
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2863000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2722000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9232000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7825000
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
14087000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
9045000
us-gaap Operating Expenses
OperatingExpenses
39281000
us-gaap Operating Expenses
OperatingExpenses
24990000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-14087000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-9045000
us-gaap Operating Income Loss
OperatingIncomeLoss
-39281000
us-gaap Operating Income Loss
OperatingIncomeLoss
-24990000
CY2024Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
826000
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
1183000
us-gaap Investment Income Interest
InvestmentIncomeInterest
2759000
us-gaap Investment Income Interest
InvestmentIncomeInterest
3611000
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-11000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
154000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-17000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
472000
CY2024Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
1000
CY2023Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
3000
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
3000
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
387000
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
814000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1334000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2739000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3696000
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13273000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7711000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-36542000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-21294000
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-31000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-13000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-46000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-50000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-13242000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-7698000
us-gaap Net Income Loss
NetIncomeLoss
-36496000
us-gaap Net Income Loss
NetIncomeLoss
-21244000
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.13
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.13
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.08
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.08
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.36
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.36
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.21
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.21
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
101282228
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
101282228
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
99325540
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
99325540
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
100616111
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
100616111
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
98880882
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
98880882
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-13242000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-7698000
us-gaap Net Income Loss
NetIncomeLoss
-36496000
us-gaap Net Income Loss
NetIncomeLoss
-21244000
CY2024Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
223000
CY2023Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
31000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
168000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-95000
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13019000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7667000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-36328000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21339000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
66174000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
822000
CY2024Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
162000
CY2024Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
223000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-13242000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
58969000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
95073000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
530000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3000
CY2023Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
31000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-7698000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
89610000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
82547000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2671000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
381000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
34000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
168000
us-gaap Net Income Loss
NetIncomeLoss
-36496000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
58969000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
107459000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1713000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
73000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
33000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-95000
us-gaap Net Income Loss
NetIncomeLoss
-21244000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
89610000
us-gaap Net Income Loss
NetIncomeLoss
-36496000
us-gaap Net Income Loss
NetIncomeLoss
-21244000
us-gaap Share Based Compensation
ShareBasedCompensation
2671000
us-gaap Share Based Compensation
ShareBasedCompensation
1713000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
262000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
259000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
109000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
88000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1070000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1774000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
180000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-10000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
3276000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
28000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2736000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2935000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-194000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1676000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-28706000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-25351000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
55643000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
55679000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
53271000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
8981000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
28000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
115000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
2344000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
46583000
trvi Proceeds From At Market Sales Net Of Commissions
ProceedsFromAtMarketSalesNetOfCommissions
9697000
trvi Proceeds From At Market Sales Net Of Commissions
ProceedsFromAtMarketSalesNetOfCommissions
1710000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
381000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
73000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
34000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
33000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
95000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
63000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
9409000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
200000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10017000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-7856000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-16345000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
13376000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
32397000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12589000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16052000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25965000
us-gaap Nature Of Operations
NatureOfOperations
<div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Nature of the Business</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Trevi Therapeutics, Inc. (“Trevi” or the “Company”) is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (“IPF”) and refractory chronic cough. Haduvio is an oral extended-release formulation of nalbuphine. Haduvio acts on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA). Kappa and mu are opioid receptors that play a key role in controlling cough hypersensitivity. Nalbuphine has been approved and marketed as an injectable for pain indications for more than 30 years in the United States (“U.S.”) and Europe. Nalbuphine’s mechanism of action also mitigates the risk of abuse associated with mu-opioid agonists because it antagonizes, or blocks, the mu-opioid receptor. Parenteral nalbuphine is not scheduled as a controlled substance in the U.S. and most of Europe.</span></p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of the expenses during the reporting periods. Significant estimates and assumptions reflected in these Condensed Consolidated Financial Statements include but are not limited to the recognition of research and development (“R&amp;D”) expenses, the valuation of stock-based awards and the valuation allowance of deferred tax assets. In addition, management’s assessment of the Company’s ability to continue as a going concern involves the estimation of the amount and timing of future cash inflows and outflows. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.</span></p>
us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
0
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2024Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
49302000
CY2024Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
139000
CY2024Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
49441000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
50603000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
29000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
58000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
50574000
CY2024Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
44640000
CY2024Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
44754000
CY2024Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
4662000
CY2024Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
4687000
CY2024Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
49302000
CY2024Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
49441000
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
49651000
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
49618000
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
952000
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
956000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
50603000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
50574000
CY2024Q3 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2023Q3 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
0
CY2024Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
0
CY2024Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
0
CY2024Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
0
CY2024Q3 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss
285000
CY2023Q4 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss
485000
CY2024Q3 trvi First Year Of Payments Square Feet Of Occupied Space
FirstYearOfPaymentsSquareFeetOfOccupiedSpace
10500
CY2024Q3 trvi Second Year Of Payments Square Feet Of Occupied Space
SecondYearOfPaymentsSquareFeetOfOccupiedSpace
11500
CY2024Q3 trvi Remaining Lease Payments Square Feet Of Occupied Space
RemainingLeasePaymentsSquareFeetOfOccupiedSpace
12500
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
973000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1137000
CY2024Q3 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
169000
CY2023Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
206000
CY2024Q3 trvi Operating And Finance Lease Right Of Use Asset
OperatingAndFinanceLeaseRightOfUseAsset
1142000
CY2023Q4 trvi Operating And Finance Lease Right Of Use Asset
OperatingAndFinanceLeaseRightOfUseAsset
1343000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
235000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
184000
CY2024Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
62000
CY2023Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
122000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
816000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1001000
CY2023Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
31000
CY2024Q3 trvi Operating And Finance Lease Liability
OperatingAndFinanceLeaseLiability
1113000
CY2023Q4 trvi Operating And Finance Lease Liability
OperatingAndFinanceLeaseLiability
1338000
CY2024Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
85000
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
85000
us-gaap Operating Lease Cost
OperatingLeaseCost
256000
us-gaap Operating Lease Cost
OperatingLeaseCost
202000
CY2024Q3 trvi Finance Lease Right Of Use Asset Amortization And Interest Expense
FinanceLeaseRightOfUseAssetAmortizationAndInterestExpense
12000
CY2023Q3 trvi Finance Lease Right Of Use Asset Amortization And Interest Expense
FinanceLeaseRightOfUseAssetAmortizationAndInterestExpense
12000
trvi Finance Lease Right Of Use Asset Amortization And Interest Expense
FinanceLeaseRightOfUseAssetAmortizationAndInterestExpense
36000
trvi Finance Lease Right Of Use Asset Amortization And Interest Expense
FinanceLeaseRightOfUseAssetAmortizationAndInterestExpense
24000
CY2024Q3 us-gaap Lease Cost
LeaseCost
97000
CY2023Q3 us-gaap Lease Cost
LeaseCost
97000
us-gaap Lease Cost
LeaseCost
292000
us-gaap Lease Cost
LeaseCost
226000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
78000
CY2024Q3 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
32000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
349000
CY2024Q3 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
32000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
368000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
377000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
95000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1267000
CY2024Q3 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
64000
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
216000
CY2024Q3 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
2000
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1051000
CY2024Q3 us-gaap Finance Lease Liability
FinanceLeaseLiability
62000
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y6M
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y3M18D
CY2024Q3 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P0Y6M
CY2023Q4 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P1Y3M18D
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.11
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.11
CY2024Q3 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.0437
CY2023Q4 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.0437
CY2024Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
78000
CY2023Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
69000
us-gaap Operating Lease Payments
OperatingLeasePayments
224000
us-gaap Operating Lease Payments
OperatingLeasePayments
162000
CY2024Q3 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
32000
CY2023Q3 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
32000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
95000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
63000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1289000
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
242000
CY2024Q3 trvi Accrued Research And Development Liabilities
AccruedResearchAndDevelopmentLiabilities
4578000
CY2023Q4 trvi Accrued Research And Development Liabilities
AccruedResearchAndDevelopmentLiabilities
1579000
CY2024Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1824000
CY2023Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1614000
CY2024Q3 trvi Accrued Consulting And Professional Fees
AccruedConsultingAndProfessionalFees
765000
CY2023Q4 trvi Accrued Consulting And Professional Fees
AccruedConsultingAndProfessionalFees
510000
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
45000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
6000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7212000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3709000
CY2024Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
47244334
CY2023Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
49223937
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5312300
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.24
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3396750
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.58
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
457500
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
2.25
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
243254
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.56
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
67828
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
2.63
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7940468
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.07
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3578089
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.81
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
4362379
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
2.47
CY2024Q3 us-gaap Share Based Compensation
ShareBasedCompensation
822000
CY2023Q2 us-gaap Share Based Compensation
ShareBasedCompensation
530000
us-gaap Share Based Compensation
ShareBasedCompensation
2671000
us-gaap Share Based Compensation
ShareBasedCompensation
1713000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-13242000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-7698000
us-gaap Net Income Loss
NetIncomeLoss
-36496000
us-gaap Net Income Loss
NetIncomeLoss
-21244000
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
101282228
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
101282228
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
99325540
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
99325540
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
100616111
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
100616111
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
98880882
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
98880882
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.13
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.13
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.08
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.08
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.36
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.36
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.21
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.21
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
17644172
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15019247
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-122355-index-headers.html Edgar Link pending
0000950170-24-122355-index.html Edgar Link pending
0000950170-24-122355.txt Edgar Link pending
0000950170-24-122355-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img65733204_0.jpg Edgar Link pending
img66656725_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
trvi-20240930.htm Edgar Link pending
trvi-20240930.xsd Edgar Link pending
trvi-ex10_2.htm Edgar Link pending
trvi-ex10_3.htm Edgar Link pending
trvi-ex31_1.htm Edgar Link pending
trvi-ex31_2.htm Edgar Link pending
trvi-ex32_1.htm Edgar Link pending
trvi-ex32_2.htm Edgar Link pending
trvi-20240930_htm.xml Edgar Link completed